Skip to Content

Project 3: Development of E1A Gene Therapy in Ovarian Cancer

Publications

Not: Bold indicates an investigator affiliated with the MD Anderson Ovarian Cancer SPORE or an Ovarian Cancer SPORE at another institution.

  1. Zhou BP, Lin SY, Chiao PJ, von Lindern RH, Spohn B, Hung MC. E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IkappaB kinases and nuclear factor kappaB activities. J Biol Chem 1999; 274:21495-8. PMID: 10419449.
    Abstract
  2. Ueno NT, Xia W, Tucker SD, Zhang S, Lopez-Berestein G, Huang L, Hung MC. Collagen-homology domain 1 deletion mutant of Shc suppresses transformation mediated by neu through a MAPK-independent pathway. Oncogene 1999;18:2617-26. PMID: 10353605.
    Abstract
  3. Shao R, Xia W, Hung MC. Inhibition of angiogenesis and induction of apoptosis are involved in E1A-mediated bystander effect and tumor suppression. Cancer Res 2000; 60:3123-6. PMID: 10866297.
    Abstract
  4. Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung, MC. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer through apoptosis involving caspase-3 pathway. Clin Cancer Res 2000; 6:250-9. PMID: 10656456.
    Abstract
  5. Meric F, Liao Y, Lee WP, Pollock RE, Hung MC. Adenovirus E1A does not induce expression of the Ewing sarcoma fusion product EWS-FLI1 in breast and ovarian cancer cell lines. Clin Cancer Res 2000; 6:3832-6. PMID: 11051226.
    Abstract
  6. Hung MC, Hortobagyi GN, Ueno NT. Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer. In: Cancer Gene Therapy, N.A. Habib (Ed.). Kluwer Academic/Plenum Publishers, 2000; 171-80. PMID: 10810625.
    Abstract
  7. Hung MC, Yan DH, Zhang S. E1A-mediated gene therapy. In: Methods in Molecular Medicine: Ovarian Cancer Methods and Protocols, J.M.S. Bartlett (Ed.). Humana Press, Inc., 2000; 775-82. [no PMID]
    [no link available]
  8. Wang SC, Hung MC. Transcriptional targeting of the HER-2/neu oncogene. Drugs Today, 2000; 36:169-75. PMID: 12856803.
    [no link available]
  9. Shao R, Tsai E-M, Wei K, von Lindern R, Chen Y-H, Hung MC. E1A inhibition of radiation-induced NF-κB activity through suppression of IKK activity and IκB degradation, independent of Akt activation. Cancer Res 2001; 61:7413-6. PMID: 11606372.
    Abstract
  10. Zhou B, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nature Cell Biology 2001; 3:245-52. PMID: 11231573.
    Abstract
  11. Zhou B, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces ubiquitination via Akt-mediated MDM2 phosphorylation. Nature Cell Biology 2001; 3:973-82. PMID: 11715018.
    Abstract
  12. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JW, Putnam JB, Weiden PL, Willey JS, Carey M, Warner DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager R.L, Sneige N, Katz RL, Daifuku R, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated adenovirus type 5 E1A gene transfer to human breast and ovarian cancer cells and its biological effects: A phase I clinical trial. J Clin Oncol 2001; 19:3422-33. PMID: 11454891.
    Abstract
  13. Ueno NT, Yu DH, Hung MC. E1A: Tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy. Breast Cancer 2001; 8:285-94. PMID: 11791119.
    Abstract
  14. Yu D, Hung MC. Anti-tumor effects of adenoviral E1A on HER2-overexpressing tumor cells. In: Oncogene Directed Therapies, 2001. Aizen J. Marrogi, Scott M. (Eds.). [no PMID]
    [no link available]
  15. Yan DW, Shao R, Hung MC. E1A cancer gene therapy. In: Gene therapy of cancer, 2nd Ed, Panner, C. (Ed.), Academic Press, San Diego, CA. 2001; pp. 465-77. [no PMID]
    [no link available]
  16. Lee W-P, Wen Y, Varnum B, Hung MC. Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis. Oncogene 2002; 21:329-36. PMID: 11821945.
    Abstract
  17. Ueno NT, Bartholomeusz C, Xia W, Anklesaria P, Bruckheimer EM, Mebel E, Paul R, Li S, Yoo G, Huang L, Hung MC. Systemic gene therapy in a human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res 2002; 62:6712-6. PMID: 12438271.
    Abstract
  18. Deng J, Kloosterbooer F, Xia WY, Hung MC. The N-terminal domain and CR2 domains of adenovirus E1A mediate two distinct mechanisms of tumor suppression. Cancer Res 2002; 62:346-50. PMID: 11809676.
    Abstract
  19. Zou Y, Peng H, Zhou B, Wen Y, Wang S-C, Tsai E-M, Hung MC. Systemic tumor suppression by the proapoptotic gene Bik. Cancer Res 2002;62:8-12. PMID: 11782349.
    Abstract
  20. Hung MC. Translational research: E1A cancer gene therapy and β-catenin prognostic marker. Drugs of Today 2002; 38(Suppl):1-35. [no PMID]
    [no link available]
  21. Chen JS, Lan K, Hung MC. Strategies to target HER2/neu overexpression for cancer therapy. Drug Resist Update 2003; 6(3);129-36. PMID: 12860460.
    Abstract
  22. Najafi SM, Li Z, Makino K, Shao R, Hung MC. The adenoviral E1A induces p21WAF1/CIP1 expression in cancer cells. Biochem Biophys Res Commun 2003; 305:1099-104. PMID: 12767945.
    Full Text
  23. Lee CM, Shvartsman H, Deavers MT, Wang SC, Xia W, Schmandt R, Bodurka DC, Atkinson EN, Malpica A, Gershenson DM, Hung MC, Lu KH. Beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecol Oncol 2003; 88(3): 363-8. PMID: 12648588.
    Full Text
  24. Liao Y, Hung MC. Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis. Mol Cell Biol 2003; 23(19): 6836-48. PMCID: PMC193925.
    Abstract
  25. Lee CM, Lo HW, Shao RP, Wang SC, Xia W, Gershenson DM, Hung MC. Selective activation of ceruloplasmin promoter in ovarian tumors: potential for gene therapy. Cancer Res 2004; 64(5): 1788-93. PMID: 14996741.
    Abstract
  26. Shao R, Lee D-F, Wen Y, Ding Y, Xia W, Ping B, Yagita H, Spohn B and Hung MC. E1A sensitizes cancer cells to TRAIL-induced apoptosis through enhancement of caspase activation. Mol Cancer Res. 2005 Apr;3(4):219-26. PMID: 15831675.
    Abstract
  27. Bartholomeusz C, Itamochi H, Yuan LX, Esteva FJ, Wood CG, Terakawa N, Hung MC, Ueno NT. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Res. 2005 Sep 15;65(18):8406-13. PMID: 16166319.
    Abstract
  28. Lo HW, Day CP, Hung MC. Cancer-specific gene therapy. Adv Genet. 2005;54:235-55. Review. PMID: 16096014.
    [no link available]
  29. Bartholomeusz C, Itamochi H, Nitta M, Saya H, Ginsberg MH, Ueno NT. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene. 2006 Jan 5;25(1):79-90. PMID: 16170361.
    Abstract
  30. Smith JA, Ngo H, Martin MC, Wolf JK. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines. Gynecol Oncol. 2005 Jul;98(1):141-5. PMID: 15963813.
    Full Text
  31. Itamochi H, Kigawa J, Kanamori Y, Oishi T, Bartholomeusz C, Nahta R, Esteva FJ, Sneige N, Terakawa N, Ueno NT. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. Mol Cancer Ther. 2007 Jan;6(1):227-35. Epub 2007 Jan 11. PMID: 17218636.
    Abstract
  32. Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC Jr, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther. 2009 Aug;8(8):2375-82. Epub 2009 Aug 11. PMID: 19671744.
    Abstract

© 2014 The University of Texas MD Anderson Cancer Center